centerforbiosimilars22h
The Banking of Biosimilars: Insights from a Leading Health Economist
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...
centerforbiosimilars1d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
BioRationality: No More Biosimilars—Just Biogenerics
Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...
centerforbiosimilars2d
Lisa Lasita, PharmD, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Derek Burns, PharmD, MBA, BCPS, BCSCP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Josh Canavan, PharmD
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Understanding Biosimilars Through Education and PBM Formulary Perspective
In an interview with Josh Canavan, PharmD, head of pharmacy at RazorMetrics, he discussed the role of pharmacy benefit managers (PBMs) in the biosimilar landscape. He emphasized the importance of PBMs ...
centerforbiosimilars4d
Biosimilars Rheumatology Roundup: January 2025
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
centerforbiosimilars4d
Skylar Jeremias
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.